Viagra (Sildenafil) Compounding Legal Status: FDA Rules, Shortage Exemptions, and What Patients Need to Know

How Sildenafil Earned FDA Approval

The FDA approved sildenafil citrate (brand name Viagra) on March 27, 1998, making it the first oral phosphodiesterase type 5 (PDE5) inhibitor cleared for erectile dysfunction (ED). The approval rested on a clinical program that enrolled thousands of men across multiple randomized trials.

The Landmark Goldstein Trial

The trial most frequently cited in the approval record is Goldstein et al. (1998), published in the New England Journal of Medicine. That study randomized 532 men with organic, psychogenic, or mixed ED to sildenafil or placebo across dose ranges of 25 mg to 100 mg 1. Men receiving sildenafil reported improved erections in 69% of attempts versus 22% with placebo. The mean scores on the International Index of Erectile Function (IIEF) erectile-function domain rose from a baseline of roughly 12.2 to 22.4 in the 50 mg and 100 mg groups, compared with 15.6 in the placebo arm 1.

Post-Approval Expansion

The FDA later approved sildenafil under the brand name Revatio (20 mg, three times daily) for pulmonary arterial hypertension (PAH) in 2005 2. That second indication matters for compounding discussions because some compounding pharmacies reference the PAH formulation when preparing non-standard sildenafil dosage forms such as oral suspensions for pediatric PAH patients.

The approval record is housed in the FDA's Drugs@FDA database, where both the original Viagra NDA (NDA 20-895) and the Revatio NDA (NDA 21-845) remain publicly accessible 3.

The Two Legal Pathways for Compounded Sildenafil

Compounding sildenafil is legal. But "legal" depends on which federal framework the pharmacy operates under. The Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the Drug Quality and Security Act of 2013, created two distinct pathways.

Section 503A: Traditional Patient-Specific Compounding

Under Section 503A, a state-licensed pharmacy may compound sildenafil for an individual patient if it holds a valid, patient-specific prescription from a licensed prescriber 4. The pharmacy cannot advertise compounded sildenafil for general sale. It cannot produce batches in anticipation of receiving prescriptions beyond limited quantities. And the compounded product cannot be a copy of a commercially available drug unless the prescriber documents a clinical difference (such as a dye-free formulation for a patient with a confirmed allergy to an inactive ingredient in the commercial tablet).

The "essentially a copy" restriction is the friction point. Because generic sildenafil 25 mg, 50 mg, and 100 mg tablets are widely available, a 503A pharmacy compounding a 50 mg sildenafil tablet without clinical justification risks FDA enforcement. Pharmacies that compound sildenafil sublingual troches, flavored oral suspensions, or combination formulations with other active ingredients generally argue those products are not copies of any commercially available form.

Section 503B: Outsourcing Facilities

Section 503B outsourcing facilities operate under a different set of rules. These FDA-registered entities may compound without patient-specific prescriptions and may distribute to healthcare facilities 5. They must follow cGMP standards, report adverse events to the FDA, and submit to regular FDA inspections.

A 503B facility may compound sildenafil in dosage forms or strengths that differ from the commercially available product. The same "essentially a copy" restriction applies, though outsourcing facilities have somewhat broader latitude when the drug appears on the FDA Drug Shortage list. Sildenafil is not on that list as of May 2026, which limits the scope of 503B compounding to non-copy formulations 6.

Why the Shortage List Matters for Sildenafil Compounding

The FDA Drug Shortage list has become the single most consequential regulatory variable for compounded versions of brand-name drugs. When a drug is listed, both 503A pharmacies and 503B outsourcing facilities gain wider latitude to compound copies of the commercially available product. When it is not listed, the "essentially a copy" restriction tightens.

The GLP-1 Precedent

The pattern became visible during the semaglutide compounding controversy of 2024 and 2025. While semaglutide appeared on the FDA shortage list, 503B outsourcing facilities compounded it at scale. Once the FDA removed semaglutide from the shortage list, enforcement attention increased 7.

Sildenafil has not appeared on the FDA Drug Shortage list in recent years. Generic competition from manufacturers including Teva, Greenstone (a Pfizer subsidiary), and multiple Indian generics has kept supply stable. This means compounded sildenafil copies of existing oral tablets face a higher enforcement risk than drugs with active shortages.

What This Means for Patients

Patients who want compounded sildenafil should confirm three things: the pharmacy is either state-licensed (503A) or FDA-registered as an outsourcing facility (503B), the prescription comes from a licensed prescriber who has evaluated them, and the compounded formulation has a documented clinical reason for differing from commercially available generics.

Patent History and Generic Timeline

Understanding when sildenafil became available outside Pfizer's exclusivity helps explain the current compounding field.

Key Patent Dates

Pfizer's original compound patent (US Patent 5,250,534) covered sildenafil citrate itself. A use patent (US Patent 6,469,012) covered its application for erectile dysfunction. Teva Pharmaceutical reached a settlement with Pfizer in 2013 that allowed Teva to launch a licensed generic on December 11, 2017, roughly two and a half years before full patent expiry 8.

Post-Patent Generic Flood

After the compound patent expired in April 2020, multiple generics entered the market. Average retail prices dropped from over $60 per tablet (brand Viagra) to $1 to $5 per tablet for generic sildenafil at many pharmacies. GoodRx data from 2024 showed generic sildenafil 100 mg tablets averaging $0.40 to $2.00 per tablet with discount coupons at major retail chains.

This price collapse reduced the economic incentive for compounded sildenafil tablets but increased demand for novel formulations (sublingual, topical, combinations) that branded and generic tablets do not offer.

What the Viagra Label Says About Safety

The FDA-approved label for sildenafil carries specific warnings and contraindications that apply regardless of whether a patient takes the branded, generic, or compounded form 9.

Contraindications

Sildenafil is contraindicated with any form of organic nitrate therapy (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate) due to the risk of severe, potentially fatal hypotension. The label also contraindicated co-administration with riociguat, a guanylate cyclase stimulator used in PAH 9.

Boxed Warning Status

Sildenafil does not carry a boxed warning. Post-marketing surveillance through the FDA Adverse Event Reporting System (FAERS) has identified signals for non-arteritic anterior ischemic optic neuropathy (NAION) and sudden hearing loss, both of which were added to the label as warnings. A 2005 FDA advisory noted reports of NAION in men taking PDE5 inhibitors, though a causal relationship has not been established 10.

Cardiovascular Considerations

The Princeton III Consensus Guidelines (2012) stratified cardiovascular risk for men seeking ED treatment. Men at low cardiac risk (able to perform moderate exercise equivalent to 3 to 5 metabolic equivalents without symptoms) were cleared for PDE5 inhibitor use. Men at high risk required cardiac stabilization first 11. This risk stratification applies equally to compounded and commercially manufactured sildenafil.

As the American Urological Association noted in its 2018 guideline update on ED, "PDE5 inhibitors should be offered as first-line therapy for most men with erectile dysfunction" 12.

Compounded Sildenafil Formulations in Practice

The compounding market for sildenafil has moved away from simple tablet copies and toward formulations that the branded and generic market does not serve.

Sublingual Troches

Sublingual sildenafil troches bypass first-pass hepatic metabolism to some degree, potentially offering faster onset than oral tablets. No FDA-approved sublingual sildenafil product exists, making troches a compounding-only formulation. Limited pharmacokinetic data from small studies suggest sublingual administration may produce detectable plasma levels 15 to 20 minutes after dosing versus 30 to 60 minutes for oral tablets, though large controlled trials have not confirmed clinically meaningful differences in onset of action 13.

Combination Formulations

Some compounding pharmacies prepare sildenafil combined with other agents such as oxytocin, PT-141 (bremelanotide), or tadalafil. These combinations are not FDA-approved. Prescribers who order them must evaluate drug interaction profiles independently, as the combinations have not undergone formal safety review.

Topical and Transdermal Forms

Topical sildenafil cream for penile application has been studied in small trials with mixed results. A randomized controlled trial by Goldstein et al. (2020) evaluated a sildenafil 3.6% topical cream (SST-6006) and found statistically significant improvement in IIEF-EF scores versus placebo in men with mild to moderate ED 14. This specific formulation is under commercial development and is not yet FDA-approved, but compounding pharmacies have prepared similar topical products under 503A authority.

FDA Enforcement History for Compounded Sildenafil

The FDA has taken enforcement actions against compounding pharmacies and supplement companies related to sildenafil, though the targets have generally been egregious violators rather than compliant 503A or 503B operations.

Tainted Supplement Warnings

The FDA's tainted supplements database lists dozens of products marketed as dietary supplements that were found to contain undeclared sildenafil or sildenafil analogs 15. These products, sold without prescriptions at gas stations and online, are illegal because they contain an unapproved new drug and bypass the prescription requirement entirely. Between 2007 and 2025, the FDA issued over 100 public notifications about tainted sexual enhancement supplements containing hidden PDE5 inhibitors.

483 Observations and Warning Letters

Several compounding pharmacies have received FDA Form 483 observations or warning letters for sildenafil-related violations, most commonly for producing compounded sildenafil that was "essentially a copy" of the commercially available tablet without clinical justification, or for insanitary conditions. The FDA's compounding inspections database tracks these actions publicly 16.

How to Verify a Compounding Pharmacy's Legal Status

Patients and prescribers can confirm whether a pharmacy is legally authorized to compound sildenafil through several public databases.

State boards of pharmacy maintain licensure records for 503A pharmacies. The FDA maintains a public list of registered 503B outsourcing facilities, searchable at FDA.gov 17. As of May 2026, approximately 70 outsourcing facilities are registered with the FDA.

Prescribers should verify that any outsourcing facility they use has not received a recent warning letter or had products recalled. The FDA's Safety Reporting Portal tracks compounding-related adverse events, and the agency publishes inspection results within its compliance database.

"Compounded preparations fill a medical need when a patient requires a medication that is not commercially available in the appropriate dosage form, strength, or formulation," the FDA states on its compounding overview page 18. That framing guides enforcement: compounding that fills a genuine clinical gap is supported, while compounding that merely copies cheaper versions of available drugs is not.